Affiliation:
1. 1Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Abstract
SummaryHLA evolutionary divergence reflects the ability to recognize diverse neoantigens as non-self, and as a biomarker is conceptually distinct from programmed cell death ligand 1 expression and tumor mutation burden. HLA-based assays to predict benefit from immunotherapy in lung cancer require prospective validation.See related article by Jiang et al., p. 4830
Publisher
American Association for Cancer Research (AACR)